Health Stocks in Motion
Updated from 2:35 p.m. EDT
Shares of NBTY (NTY) were among the best-performing health and pharmaceutical stocks Monday, rising 11.9% after the company released preliminary fourth-quarter sales results.
The maker of nutritional supplements posted preliminary sales of $426 million, up significantly from the year-ago period, when it turned in sales of $365 million. Analysts polled by Thomson First Call were expecting fourth-quarter sales of $394.1 million. Shares of NBTY traded up $2.71 to $25.40.
Euro Tech Holdings (CLWT) rose 10.2% after the company signed two contracts to supply flow injection analyzers and sample preparation equipment for water quality analysis. The contracts, worth about $1.9 million, were awarded by the State Environmental Protection Agency of the People's Republic of China. The equipment will be supplied and installed in monitoring stations around various parts of China by the end of the year. Shares traded up 27 cents to $2.92.Shares of Cytyc (CYTC) rose 5.4% after the company announced a multi-year deal with LabOne (LABS). The deal calls for Cytyc's ThinPrep Imaging Systems to be placed within a LabOne lab in the Kansas City area. The location is the highest volume, single-site testing lab in the country, Cytyc said. The ThinPrep system is used to improve cancer screening efficiency and performance. Shares traded up $1.30 to $25.23. Johnson & Johnson (JNJ) traded actively after the company announced that its Ortho Biotech Products unit received a subpoena from the Office of the Inspector General for the Department of Health and Human Services. The subpoena for documents is related to the sales and marketing of Procrit, a treatment that's used for anemia. Johnson & Johnson said that it is cooperating with regulators. Shares traded up 25 cents to $57.25. Other health care volume movers included Merck (MRK), up 92 cents to $34.23; Schering-Plough (SGP), down 45 cents to $18.50; Amgen (AMGN), down 13 cents to $57.63; Pfizer (PFE), up 33 cents to $31.30; and Genentech (DNA), up 83 cents to $53.99.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV